Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — 16th Annual Needham Technology & Media Conference (May 2021)
23 slides from Simulations Plus's conference presentation, May 20, 2021
Slide 1: 16th Annual Needham Technology & Media Conference
1 | NASDAQ: SLP 16 th Annual Needham Technology & Media Conference Shawn O’Connor, CEO May 20, 2021
Slide 2: Safe Harbor Statement
2 | NASDAQ: SLP With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . The actual results of the Company could differ significantly from those statements . Factors that could cause o
Slide 3: Mission
3 | NASDAQ: SLP Our mission is to create value for our customers by accelerating and reducing the costs of R&D through innovative science - based software and consulting solutions that optimize treatment options and improve patient lives . Mission
Slide 4: Company Overview
4 | NASDAQ: SLP □ Industry - leading provider of modeling and simulation solutions used by major pharmaceutical, biotech, chemical, consumer goods companies and regulatory agencies worldwide □ Innovative software and services to improve drug development from discovery to regulatory approval with sup
Slide 5: Our Value Proposition
5 | NASDAQ: SLP Our solutions allow customers to model and predict results of chemical and biological tests required in the R&D process to improve success rates at multiple points in the process: – Computational AI models help scientists streamline and improve their processes – Machine learning impr
Slide 6: We Improve Drug Discovery and Development
6 | NASDAQ: SLP We Improve Drug Discovery and Development
Slide 7: PBPK Software Solutions and AI Data Mining
7 | NASDAQ: SLP PBPK Software Solutions and AI Data Mining Simulating IV, oral, oral cavity, ocular, inhalation, skin and IM absorption, PBPK, PBBM, PD modeling and drug - drug interactions QSAR modeling enabling rapid prediction of 140+ ADMET properties Used for lead generation and optimization Mec
Slide 8: PKPD Software Solutions
8 | NASDAQ: SLP PKPD Software Solutions Population PKPD Model to support dose regimen, risk exposure, clinical trial protocol design and analysis, drug label specifications and regulatory submission Cloud - based data management application Datxplore PKanalix Mlxplore Monolix Simulx Exploration and
Slide 9: QSP/QST Software Solutions
9 | NASDAQ: SLP QSP/QST Software Solutions Determine potential drug - induced liver injury hazard posed by individual drug candidates to support clinical trial optimization Assess the potential for drug - induced kidney injury of drug candidates to support clinical trial optimization and clinical tr
Slide 10: Services Solutions
10 | NASDAQ: SLP • 70+ scientific PhD experts provide insightful solutions to improve the productivity of science - based drug development • Focusing on lead selection, pharmacology, ADMET and DMPK, dose regimen, efficacy and safety • Capabilities include: – Population PKPD data assembly, modeling,
Slide 11: Janssen Case Study: Accelerating Regulatory Interactions
11 | NASDAQ: SLP Janssen Case Study: Accelerating Regulatory Interactions Virtual crossover trials to establish drug product specification after manufacturing changes • Janssen changed the manufacturing process to improve efficiencies with scale - up techniques post approval • FDA requested clinical
Slide 12: In Silico Methods Improve the Probability of Phase Success
12 | NASDAQ: SLP In Silico Methods Improve the Probability of Phase 3 Success Client Case Study: Strategic Use of Modeling & Simulation • Client with novel antibody for prophylactic use in competitive migraine market had Phase 3 development plan with predicted probability of success of <15% • Iterat
Slide 13: Growth Drivers
13 | NASDAQ: SLP Growth Drivers Increasing acceptance of modeling and simulation by FDA and drug industry High customer satisfaction with ~95% software contract renewal rate (by fees) Recently improved and expanded sales infrastructure Increasing opportunities for product and service cross - selling
Slide 14: Consistent Revenue Growth
14 | NASDAQ: SLP $14.9 $17.0 $18.5 $21.6 $14.0 $9.2 $12.7 $15.5 $20.0 $9.8 FY17 FY18 FY19 FY20 FY21 YTD Software Services Consistent Revenue Growth FY21 YTD (through Q2) (in millions) $24.1 $29.7 $34.0 $23.8 $41.6
Slide 15: Software and Services Performance
15 | NASDAQ: SLP Software and Services Performance FY21 YTD (through Q2) Software Products % of Software Revenues 56% 19% 17% 8% GastroPlus Monolix Suite ADMET Predictor Other Software 19% 29% 52% PBPK QSP/ QST PKPD Services Offerings % of Services Revenues 59% of Total Revenue 41% of Total Revenue
Slide 16: Global Customer Base
16 | NASDAQ: SLP Global Customer Base 66% Americas 23% EMEA 11% Asia Pacific Revenue by Region FY21 YTD (through Q2)
Slide 17: Strategic Opportunities for Expansion and Growth
17 | NASDAQ: SLP • Expand product offerings through opportunistic acquisitions – Fill gaps in the current product offerings – Focus on immediately or near - term accretive opportunities – Fragmented industry amenable to consolidation • Further expand global sales reach – Increase sales effort to dri
Slide 18: FY21 Q2 YTD Performance & FY21 Full Year Guidance
18 | NASDAQ: SLP • Total Revenue Growth – YTD performance: 21% y/y growth – Full - year guidance range: 15 - 20% y/y organic growth plus 3 - 5% from Lixoft • Software Revenue Growth – YTD performance: 40% y/y growth – Full - year guidance range: 20 - 25% y/y growth • Services Revenue Growth – YTD pe
Slide 19: Investment Highlights
19 | NASDAQ: SLP x Leading provider of innovative modeling and simulation software and consulting services focused on pharmaceutical and biotechnology companies » Solutions from early discovery through regulatory approval x Pure play in the in silico drug discovery space x Growing acceptance of tech
Slide 20: Financial Summary and Selected Financial Information
20 | NASDAQ: SLP Financial Summary and Selected Financial Information Nasdaq Global Select Market SLP Q2 Cash and short - term investments $118M Q2 Borrowed Debt Outstanding $0 Market Capitalization (a/o 5/12/21) $1.1B Q2 Fully Diluted Shares Outstanding 20.8M 30 - Day Avg. Daily Trading Volume (a/o
Slide 21: Covering Analysts
21 | NASDAQ: SLP Covering Analysts Bank Analyst Craig - Hallum Matt G. Hewitt Oppenheimer & Co. Francois Brisebois Raymond James Dane Leone
Slide 22: Q&A Questions & Answers Thank you!
22 | NASDAQ: SLP Q&A Questions & Answers Thank you!
Slide 23: References
23 | NASDAQ: SLP 1. J Health Econ . 2016 May;47:20 - 33. 2. Brochure: “Biopharmaceutical Research & Development: The Process Behind New Medicines” . PhRMA. 3. EvaluatePharma® World Preview 2017, Outlook to 2022, 10th Edition, June 2017, p. 19. References
Simulations Plus — 16th Annual Needham Technology & Media Conference (May 2021) on 6ix